Shares of the company are trading at $3.06 a bit higher than $2.86, the stock’s 50 day moving average and which is significantly higher than the 200 day moving average of $2.62. The 50 day moving average moved up $0.20 and the 200 day average went up by +16.74%. 42K shares changed hands in the last trading session. Shares saw a steep decrease in trading volume of 64.07% under the normal average daily volume.
Traders are a little more bullish on shares of Prana Biotechnology Ltd – Ameri if you pay attention to the downtick in short interest. The stock had a fall in short interest of -8.14% as of October 13, 2017 from the last reporting period. Short interest decreased 6,575 over that period. Days to cover decreased 0.0 to 6.0 and the percentage of shorted shares was 0.05% on October 13.
The following firms have recently changed their position in PRAN. Bank Of America Corp /de/ reduced its investment by selling 166 shares a decrease of 15.1% as of 06/30/2017. Bank Of America Corp /de/ owns 933 shares worth $2,000. The value of the position overall is down by 33.3%. Citadel Advisors LLC trimmed its position by shedding 11,211 shares a decrease of 48.2% from 12/31/2016 to 06/30/2017. Citadel Advisors LLC claims 12,069 shares with a value of $28,000. The total value of its holdings decreased 26.3%.
Ubs Group Ag divested its ownership by shedding 3,198 shares a decrease of 89.4%. Ubs Group Ag now holds 378 shares valued at $1,000. The value of the position overall is down by 90.9%.
Prana Biotechnology Limited, launched on November 11, 1997, is a development-stage medical biotechnology company. The Company is involved in the research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer’s disease, Huntington disease, Parkinson’s disease and other neurological disorders. The Business’s lead product candidates are PBT2 and PBT434. The Business’s lead drug candidate PBT2 is being developed for the treatment of Alzheimer’s and Huntington’s diseases. The Company also has advanced a drug candidate for Parkinson’s disease and other movement disorders (PBT434) and brain cancer (PBT519), which are in pre-clinical toxicology testing. Its other applications for its therapies include certain cancers, age-related macular degeneration, Motor Neuron disease, Creutzfeldt-Jakob disease (the human variant of Mad Cow disease), and a range of orphan neurodegenerative disorders. PBT2 is a small molecule that reversibly binds and transports copper and zinc within neurons and across synapses..